Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Treatment of Femoropopliteal Lesions with Drug-Coated Balloons: IVUS vs. Conventional Angiography

Angiography has traditionally been the standard imaging technique to guide endovascular therapy (EVT) in patients with peripheral arterial disease. However, its capacity is limited to showing 2D images of the vascular lumen, without providing any information on complete vessel structure. This hinders the precise choice of device, balloon, or stent size, as well as the adequate assessment of procedural outcomes.

Intravascular ultrasound (IVUS) provides detailed information on vascular dimensions and plaque characteristics. Its use has been shown to improve clinical outcomes in the treatment of complex coronary lesions and, in recent years, it has also been expanded to the management of peripheral arterial disease. However, clinical evidence supporting the use of IVUS compared with standard angiography in peripheral artery interventions remains limited.

The aim of this prospective, multicenter, randomized study was to compare the outcomes of IVUS versus conventional angiography in the treatment of femoropopliteal lesions, considering different levels of complexity.

The primary endpoint (PEP) was target-lesion primary patency, defined as the absence of clinically driven target-lesion revascularization (CD-TLR) or restenosis at 12 months. The secondary endpoint (SEP) included the incidence of CD-TLR, as well as clinical and hemodynamic improvement parameters.

Read also: Coronary Events after TAVI according to the FRANCE Registry.

A total of 237 patients were included in the IVUS-DCB study and treated with drug-coated balloon angioplasty for femoropopliteal lesions. Of these subjects, 158 had complex lesions (TASC II type C/D) and 79 had non-complex lesions (TASC II type A/B).

In the group with complex lesions, the use of IVUS was associated with significantly higher rates of primary patency (82.1% vs. 60.3%; hazard ratio [HR]: 0.34; 95% confidence interval [CI]: 0.16–0.70; p = 0.002), lower incidence of CD-TLR (90.0% vs. 76.9%; HR: 0.31; 95% CI: 0.13–0.75; p = 0.01), and sustained clinical and hemodynamic improvement compared with angiographic guidance.

In the group with non-complex lesions, there were no significant differences in either primary patency (87.5% vs. 88.2%; HR: 1.84; 95% CI: 0.39–8.60; p = 0.44) or secondary endpoints between patients guided by IVUS and those guided by angiography.

Conclusion

The use of IVUS in drug-coated balloon angioplasty was associated with higher rates of primary patency and clinical improvement in complex femoropopliteal lesions, without significant differences in cases of non-complex lesions compared with angiographic guidance.

Original Title: Intravascular Ultrasound-Guided vs Angiography-Guided Drug-Coated Balloon Angioplasty in Patients With Complex Femoropopliteal Artery Disease.

Reference: Seung-Jun Lee, MD et al JACC Cardiovasc Interv. 2025;18:558–569.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Andrés Rodríguez
Dr. Andrés Rodríguez
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...